key: cord-0801756-ajx1uxut authors: Rezabakhsh, Aysa; Mahmoodpoor, Ata; Soleimanpour, Hassan title: Historical perspective of aspirin: A journey from discovery to clinical practice Ancient and modern history date: 2021-04-17 journal: J Cardiovasc Thorac Res DOI: 10.34172/jcvtr.2021.28 sha: 3d33b4e5607078c1ef2415b6ac853ee2f9c3dfa7 doc_id: 801756 cord_uid: ajx1uxut nan ASA administration in treatment of various cancers, inflammatory disorders (e.g., Kawasaki diseases, acute rheumatic fever, and pericarditis), preeclampsia, HIV (human immunodeficiency virus), as well as COVID-19 (Coronavirus disease 2019) have been also well-established. Similarly, Craven confirmed the administration of ASA to prevent effectively the recurrent MI and cerebrovascular events, as well. 3 Despite these advantages, some side effects such as GI bleeding, worsening the asthma, Reye's syndrome, intracranial hemorrhage, tinnitus, and drug interactions most likely with other NSAIDs have been also reported. In 1975, Samuelsson, a Swedish biochemist, indicated that aspirin could exert an antiplatelet effect by inhibition of thromboxane A2. 4 In line with this finding, cyclooxygenase isoenzymes were also isolated, which are mainly responsible for prostanoids synthesis from arachidonic acid that can be irreversibly inhibited by aspirin. In 1974, Peter Elwood, an epidemiologist at the UK Medical Research Council, designed the first randomized controlled trial about the potential therapeutic effect of aspirin (300 mg/day) in 1,239 patients with myocardial infarction (MI). the results showed a significant reduction in total mortality, by 12%, and 25% after 6 and 12 months, respectively. 5 In 1980, a meta-analysis of six randomized clinical trials also revealed that aspirin could decrease the risk of re-infarction by 21% in 10,000 patients with MI. In the second International Study of Infarct Survival (ISIS-2) trial, the impact of aspirin alone (162 mg/day) and in combination with the intravenous streptokinase (1.5 million IU) was evaluated on 17,187 patients for the reduction of mortality and the recurrence events after acute myocardial infarction (AMI). 6 The results indicated a relative risk reduction in patients with re-infarction up to 23% in aspirin and 42% in combination group, as well. 6 The importance of these findings prevailed in 1982 when Figure 1 ). Together, these benefits were led to the Food and Drug Administration's approval in 1985, for both treatment and the secondary prevention of AMI. According to a published result of ASPREE (Aspirin in Reducing Events in the Elderly) clinical trial, administration of aspirin in healthy elderly people could not prolong the disabilityfree survival rate, while led to a higher rate of major hemorrhage than placebo; therefore, in early 2019, the American Heart Association and American College of Cardiology issued a declaration to modify the clinical practice guidelines, regarding the routine administration of aspirin in the elderly subgroup (≥ 70 years), who do not have underlying cardiovascular disease but are at the higher risk for bleeding. Figure 1 . A legendary image represents the scientists who play an important role in aspirin discovery and development. The aspirin story-from willow to wonder drug Aspirin: a historical and contemporary therapeutic overview The discovery of aspirin's antithrombotic effects Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides A randomized controlled trial of acetyl salicylic acid in the secondary prevention of mortality from myocardial infarction Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2 The authors declared that they have no conflict of interest regarding this study. Not applicable. Not applicable.